Gastric cancer is the fourth most common cancer and second leading cause of cancer deaths (∼700 000 deaths annually) worldwide ([@bib26]). *Helicobacter pylori* is now well known as an important pathogen related to the development of gastric cancer, and the effect of *H. pylori* eradication on reducing gastric cancer incidence is related to the risk existing at the time of eradication therapy ([@bib9]; [@bib44]). In a Japanese multicenter clinical study, the incidence of new cancers after endoscopic mucosal resection of an early gastric cancer was reduced by one-third among those with *H. pylori* eradication compared with no eradication therapy ([@bib7]). However, the study also confirmed that *H. pylori* eradication did not completely prevent development of gastric cancer, and the prevalence of metachronous gastric cancer within 3 years after successful eradication was 3.3%. The previous studies reported the prevalence of metachronous gastric cancer within 3 years about 9% ([@bib44]; [@bib23]), and the patients with recent history of endoscopic treatment for gastric cancer are known to have evidently greater risk compared with the patients with mild atrophy related to persistent *H. pylori* infection in Japan. The high prevalence of gastric cancer in Japan has led to a gastric cancer screening program that has shown benefits in terms of a decreased risk of mortality from gastric cancer through the detection of malignant lesions in the early stage in the screened population ([@bib40]). Cancer screening has proven to be a high-cost endeavour and thus there has been continuing interest in developing non-invasive screening tests to identify the populations most likely to benefit. Measurement of serum pepsinogen (PG) or serum antibody against *H. pylori* is now considered as valid methods for identification of patients for screening for gastric cancer in terms of cost benefit and accuracy ([@bib17]; [@bib18]; [@bib27]). Pepsinogen I is produced by the chief and mucous neck cells in the fundic glands and PG II is produced by these cells and also by the cells in the pyloric glands and Brunner\'s glands ([@bib37], [@bib38]). Progressive mucosal damage results in a progressive decline in PG I levels and in the ratio of PG I to PG II (PG I/II) such that measuring PG levels can non-invasively identify the presence of atrophic gastritis and thus enhance the detection of positive cases in gastric screening programs ([@bib28], [@bib29]). However, cumulative data have shown some limitations, one of which is that the predictive value of PG as gastric cancer risk marker is reduced following *H. pylori* eradication as *H. pylori* eradication can significantly change PG levels with a decrease of PG I and PG II and an increase of PG I/II even in those at high risk for gastric cancer ([@bib15]; [@bib13]). As such no validated predictive non-invasive biomarkers for gastric cancer after *H. pylori* eradication are yet available. In a longitudinal cohort study conducted in *H. pylori*-infected middle-aged Japanese men to evaluate the preventive effects of *H. pylori* eradication on the development of gastric cancer using PG test-positive criteria PG I ⩽70 ng ml^−1^ and PG I/II ⩽3.0. Significant reduction (*P*\<0.05; log-rank test) in cancer incidence after *H. pylori* eradication was observed only in PG test-negative subjects (PG I \>70 ng ml^−1^ or PG I/II \>3.0) ([@bib52]). Cancer development both before and after *H. pylori* eradication seems to depend on the presence of extensive atrophy such that patients with a medical history of endoscopic submucosal dissection (ESD) are thought to be high-risk group for gastric cancer even after *H. pylori* eradication. Non-invasive biomarkers to identify those at highest risk among this already high risk group are needed.

Micro-RNAs (miRNAs) are 18--25 nucleotide noncoding RNA sequences that are transcribed but not translated into proteins. Some miRNAs have been shown to possess oncogenic or tumour suppressor activity and relate to apoptosis, proliferation, differentiation, metastasis, angiogenesis and immune response, which are all potentially involved in cancer initiation, progression and treatment response ([@bib22]; [@bib48]). There have been an increasing number of studies showing overexpression or downregulation of specific miRNAs in various malignant tumours including gastric cancer and *H. pylori*-infected gastric mucosa ([@bib32]; [@bib10]; [@bib14]; [@bib42]).

MiRNAs can be detected circulating in a cell-free form in blood, most probably in exosomes which protect them against degradation by ribonuclease (Rnase), and their signatures in blood are similar in men and women, as well as individuals of different age ([@bib5]; [@bib11]; [@bib30]). Furthermore, miRNA levels are similar in plasma and serum, and freeze/thaw as well as prolonged storage at room temperature does not affect their levels ([@bib30]). Thus, serum miRNAs have the potential of a novel biomarker for many cancers, including gastric cancer ([@bib30]; [@bib31]; [@bib21]; [@bib4]). Accumulating evidence also suggest the potential of miRNAs in the early detection of patients with malignancies such as lymphoma, colorectal cancer, tongue cancer and ovarian cancer ([@bib19]; [@bib50]; [@bib31]; [@bib35]). However, there are few papers reporting the value of serum miRNAs in early detection of gastric cancer ([@bib20]; [@bib46]). Our goal was to examine serum miRNAs as markers to individuals at high risk for gastric cancer not only before *H. pylori* eradication but also after eradication.

Materials and Methods
=====================

This was a case--control study of patients with a recent history of ESD for early gastric cancer and non-cancer controls. Patients were enrolled for the study between October 2006 and September 2012.

Patients
--------

Patients with recent medical history of ESD for early stage, non-cardia intestinal-type gastric cancer without lymph node metastasis were enrolled as the high-risk group for gastric cancer. The control group consisted of subjects who had been previously diagnosed as *H. pylori*-positive gastric ulcer or atrophic gastritis. Exclusion criteria included *H. pylori* eradication within 1 year, gastrectomy, renal failure, cirrhosis or other malignant diseases. Demographic data collected at study entry included age, gender, smoking habit, alcohol consumption, drug treatments and eradication history. Drinking and smoking were defined as 'regular\' when consumption was more than 35 **g** for ethanol or 5 cigarettes per day, respectively. The study was approved by the Osaka Medical Center for Cancer and Cardiovascular Diseases Ethical Committee and Kawasaki Medical School Ethical Committee and written informed consent was obtained from each patient.

RNA extraction and quantitative polymerase chain reaction
---------------------------------------------------------

Five ml of peripheral blood was collected just before endoscopy, and 1--4 h after collection the serum was separated by centrifugation and were stored at −80 °C until use. Total naked circulating RNA was extracted from 800 *μ*l of serum using QIAamp Circulating Nucleic Acid kits (QIAGEN K. K., Tokyo, Japan), and finally eluted into 25 *μ*l of elution solution according to the manufacturer\'s protocol. We examined 20 miRNAs (Let-7, miR-17-92 cluster, miR-21, miR-106b-25 cluster, miR-141, miR-143, miR-194, miR-203, miR-204, miR-205, miR-214, miR-223, miR-375) that were evaluated in the previous study ([@bib43]) and additionally miR-221 and miR-744 that had been recently reported as serum biomarkers for early detection of gastric cancer in China ([@bib46]). Expression levels of miRNAs were analysed by quantitative reverse-transcriptase PCR (qRT--PCR). cDNA was prepared from total RNA using a TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Predesigned TaqMan MicroRNA Assays including primer set and TaqMan probe were purchased from Applied Biosystems. PCR was performed using TaqMan Universal PCR Master Mix II, and all reactions were run in triplicate on the 7900HT Fast Real-Time PCR system (Applied Biosystems). The cycle passing threshold (Ct) was recorded for each candidate miRNAs, and U6snRNA and miR-16 were used as the endogenous control for data normalisation. Relative expression of the target miRNAs was calculated using the comparative threshold cycle method.

Assay for serum levels of PG I and II
-------------------------------------

Serum levels of PG I and II were measured using enzyme-linked immunosorbent assay (ELISA) kits (LS test Eiken Kagaku, Inc., Tokyo, Japan).

Diagnosis of *H. pylori*
------------------------

Venous blood samples were analysed for specific IgG *H. pylori* antibodies with ELISA kits using the E plate test (Eiken Kagaku, Inc.). Patients were considered to be infected with *H. pylori,* if the serum test was positive combined with evidence of chronic gastritis or atrophy with *H. pylori* on histopathological examination. Post eradication was confirmed by a negative ^13^C-urea breath test (^13^C-UBT) or negative serum *H. pylori* antibodies combined with history of the completion of *H. pylori* eradication therapy.

Statistical analyses
--------------------

Values are expressed as the mean±s.d. or the median with a 25--75% range, whichever was appropriate depending on whether the data were normally distributed. Mantel--Haenszel *χ*^2^-analysis and the unpaired *t-*test were performed to measure differences in demographic and clinical characteristics. Statistical analyses for significant differences of miRNA levels were performed using the nonparametric Mann--Whitney *U-*test between the two groups and the Wilcoxon\'s signed rank test for paired data. Receiver--operator characteristic curves (ROC) were obtained to establish the most suitable cutoff point. Mantel--Haenszel statistics were used to assess the relationship between the high-risk group and the serum levels of miRNAs and PG showing the odds ratio (OR) and 95% confidence interval (CI). A two-sided *P*-value of less than 0.05 was considered statistically significant. All statistical computations were performed using SPSS (SPSS Inc., Chicago, IL, USA).

Results
=======

Eighty-seven patients with a prior ESD history for non-cardiac early gastric cancer as a high risk group and 114 controls who were matched to the high-risk group by gender and age were enrolled. Serum samples were taken from those patients before and 1 year after eradication. In the high-risk group, serum samples were taken before eradication in 25 patients, after eradication in 23 and both in 39. In the controls, samples were taken before eradication in 44 patients, after eradication in 50 and both in 29. Demographic and clinical characteristics of the study groups are shown in [Table 1](#tbl1){ref-type="table"}.

Using U6snRNA as an endogenous control for data normalisation, none of the miRNAs levels were significantly different between the two groups. In contrast, using miR-16 as an endogenous control, the relative levels of miR-106b before (8.46 × 10^−2^ *vs* 4.70 × 10^−2^, *P*=0.03) and after (7.19 × 10^−2^ *vs* 3.11 × 10^−2^, *P*\<0.001) *H. pylori* eradication, miR-21 after eradication (4.79 × 10^−2^ *vs* 2.90 × 10^−2^, *P*=0.003), and let-7d before (0.63 × 10^−2^ *vs* 0.46 × 10^−2^, *P*=0.03) and after (1.33 × 10^−2^ *vs* 0.79 × 10^−2^, *P*=0.02) were significantly higher in the high-risk group than those in the controls ([Table 2](#tbl2){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}). The other examined miRNAs levels were not significantly different between the two groups ([Table 2](#tbl2){ref-type="table"}). In the controls, miR-106b significantly decreased (*P*=0.03) and let-7d increased (*P*=0.03) after *H. pylori* eradication ([Figure 2](#fig2){ref-type="fig"}), although other miRNAs did not significantly change after eradication. In the high-risk group, miR-21 significantly decreased (*P*=0.03) after *H. pylori* eradication ([Figure 2](#fig2){ref-type="fig"}), although other miRNAs did not significantly change.

Serum PG I levels (before eradication 35.1 *vs* 55.3, *P*=0.01, after 31.7 *vs* 41.9, *P*=0.01) and PG II were significantly lower in the high-risk group than those in the controls both before and after eradication. Pepsinogen I/II were significantly lower (4.70 *vs* 5.25, *P*=0.01) in the high-risk group than those in the controls after eradication, but nor before eradication ([Table 3](#tbl3){ref-type="table"}). Serum PG I (*P*=0.008 in the controls and *P*=0.001 in the high-risk group) and PG II levels significantly decreased and PG I/II significantly increased (*P*=0.003 in the controls and *P*\<0.001 in the high-risk group) in the both groups after eradication ([Figure 3](#fig3){ref-type="fig"}).

Determination of cutoff points for screening for gastric cancer
---------------------------------------------------------------

Receiver--operator characteristic curve analyses revealed that miR-106b levels before (the area under the ROC curve (AUC) 0.61; 95% CI: 0.51--0.71, *P*=0.03) and after eradication (AUC 0.70, 95% CI: 0.60--0.79, *P*\<0.001), let-7d before (AUC 0.62, 95% CI: 0.52--0.72, *P*=0.02) and miR-21 after (AUC 0.72, 95% CI: 0.57--0.85, *P*=0.004) were the valuable biomarkers for differentiating high-risk individuals from controls ([Figure 4](#fig4){ref-type="fig"}). The suitable cutoff points of miR-106b for differentiating high-risk individuals obtained by an ROC were 0.075 and 0.032 before and after *H. pylori* eradication, respectively. Using the suitable cutoff point, the sensitivity and specificity of screening for high-risk group were 55.6% and 70.3% before *H. pylori* eradication (OR=2.96, 95% CI: 1.42--6.15, *P*=0.004) and 75.8% and 51.4% after eradication, respectively (OR=3.32, 95% CI: 1.57--7.00, *P*=0.002). The most suitable cutoff points of miRNAs for differentiating high-risk individuals obtained by an ROC after eradication was a miRNA-21more than 0.04, and the sensitivity and specificity were 58.6% and 86.1%, respectively (OR=8.78, 95% CI: 2.65--29.1, *P*\<0.001). The most suitable cutoff points of miR-106b combined with miR-21 after eradication were a miR-106b more than 0.032 and miR-21 more than 0.02, and the sensitivity and specificity were 69.0% and 69.4%, respectively (OR=5.05, 95% CI: 1.75--14.6, *P*=0.003) ([Table 4](#tbl4){ref-type="table"}).

The most suitable cutoff points of PG were a PG I concentration less than 45 ng ml^−1^ before eradication and PG I less than 40 ng ml^−1^ combined with PG I/II less than 6.0 after eradication. Using the most suitable cutoff point, the sensitivity and specificity of screening for high-risk group were 62.3% and 63.8%, before eradication (OR=2.91, 95% CI: 1.38--6.13, *P*=0.005) and 67.8% and 61.8% after eradication, respectively (OR=3.40, 95% CI: 1.63--7.08, *P*=0.001) ([Table 4](#tbl4){ref-type="table"}).

Discussion
==========

[@bib19] first discovered tumour-specific deregulation of circulating miRNAs and subsequently, circulating miRNAs have been suggested great potential as biomarkers for many cancers including gastric cancer ([@bib30]; [@bib31]; [@bib21]; [@bib4]). Moreover, accumulating reports suggest the potential of miRNAs in the early detection of patients with several malignancies including gastric cancer ([@bib31]; [@bib35]; [@bib20]); however, the value of circulating miRNAs as biomarker for detection of high risk of gastric cancer has not been reported yet. In the present study, we first indicated the association between circulating miRNAs and high risk for gastric cancer demonstrating that the miR-106b and let-7d before and after *H. pylori* eradication and miR-21 after eradication were significantly higher in the high-risk group than those in the controls.

The miR-106b-25 cluster (miR-106b, miR-93 and miR-25) and miR-21 are oncogenic and are abnormally upregulated in gastric cancer ([@bib1]; [@bib48]; [@bib51]). Targets of miR-106b-25 include cyclin-dependent kinase inhibitor (CDKN1A; p21^CIP1/WAF1^), E2F1, and proapoptoic factor Bim leading to a decreased response of gastric cells to TGF-*β*, ([@bib34]; [@bib16]) and miR-21 targets and inhibits tropomyosin 1 (alpha) (*TPM1*), programmed cell death 4 (neoplastic transformation inhibitor) (*PDCD4*), and phosphatase and tensin homologue (*PTEN*) and other tumour-related genes. ([@bib53]; [@bib6]; [@bib49]) and ([@bib47]) reported that the plasma concentrations of miRNAs, miR-17-5p, miR-21, miR-106a and miR-106b were significantly higher in 69 gastric cancer patients than in 30 healthy controls indicating the greatest AUC value for miR-106b by ROC analysis. In contrast, the let-7 family acts as tumour suppressors ([@bib3]; [@bib8]), and the target genes are oncogenes such as high mobility group A2 (HMGA2), Ras, C-Myc and so on, and reduction of let-7 leads to overexpression of the oncogenes contributing to carcinogenesis ([@bib12]; [@bib25]; [@bib39]).

The results of serum miR-106b in the present study were similar to the results in our previous study investigating miRNAs expression in the gastric mucosa. The oncogenic miRNAs (miR-17/92 and miR-106b-93-25 cluster, miR-21, miR-194 and miR-196) levels were significantly higher in the gastric mucosa of the high-risk group compared with controls irrespective of *H. pylori* eradication. *H. pylori* eradication resulted in a significant fall in the oncogenic miRNAs only in the gastric mucosa of the controls, whereas let-7d expression increased in both groups ([@bib43]). In the present study, serum miR-21 expression levels even in the high-risk group decreased after eradication and associated with cancer risk, and the other oncogenic serum miRNAs were not significantly associated with risk for gastric cancer. Interestingly, a recent study detected increased levels of serum miR-21 in patients with chronic hepatitis C virus infection (CHC) and no difference compared with CHC-associated hepatocellular carcinoma. *H. pylori* by itself or related inflammation may strongly associate with serum miR-21 levels, and serum miR-21 levels could be an available biomarker to detect high-risk group only after successful eradication.

In our study, serum let-7d levels were significantly higher in the high-risk group than in controls irrespective of *H. pylori* eradication and increased after eradication in the controls. Let-7 family expression levels have been shown to be negatively associated with histological scores for activity, chronic inflammation and *H. pylori* density ([@bib24]). *H. pylori* containing the cagPAI have been speculated to decrease let-7 expression in the gastric epithelium via the pivotal mitogen-activated protein kinase and nuclear factor-κB ([@bib36]; [@bib33]; [@bib24]). One study suggested that serum let-7a concentrations (not normalised by endogenous controls) were significantly lower in those with cancer compared with controls ([@bib47]). However, another study reported that let-7e levels (normalised to the spiked-in cel-miR-39) were significantly higher in cancer thus confirming our results ([@bib46]). We suspect that the different results in let-7 levels in relation of cancer are likely related to normalisation with endogenous controls.

More recently, [@bib46] using miRNA profiling in a population-based study in China identified a panel of three serum miRNAs (miR-221, miR-744 and miR-376c) as potential biomarkers for early detection of gastric cancer indicating that only miR-221 was significantly elevated in those with dysplasia. However, there is no association between the miR-221 levels and high risk for gastric cancer both before and after eradication. The suitable biomarker to detect high risk of gastric cancer may differ depending on populations. However, the results of another profiling study identifying specific miRNAs in China were not consistent and miR-378 was distinguished as a novel biomarker in early detection of gastric cancer ([@bib20]).

In the present study, *H. pylori* eradication significantly changed serum PG levels even in the high-risk group, whereas eradication did not significantly alter miR-106b and let-7 levels in the high-risk group. The serum miRNAs seem to be equivalent or even superior to serum PG as the biomarkers to detect a group at high risk for gastric cancer, especially after eradication. In a recent Japanese multicenter clinical study to investigate the incidence of new gastric cancers occurring after endoscopic treatment of an early gastric cancer, the incidence of new gastric cancers was reduced by one-third among those with *H. pylori* eradication compared with no eradication therapy. The study also confirmed that the incidence of new gastric cancer was 3.3% and quite high even after successful eradication ([@bib7]). Our previous study, which reported the prevalence of metachronous gastric cancer within 3 years was about 9%, indicated that severe atrophy assessed by histology and lower levels of serum PG I before eradication were predictive factors for metachronous gastric cancer in high-risk patients after successful eradication. Non-invasive biomarkers to identify those at highest risk among this already high-risk group are needed, and continued surveillance (secondary prevention) should be considered ([@bib41]). The serum miR-106b and miR-21 seem to be suitable non-invasive markers before and after eradication, respectively, and the combination of these miRANs after eradication seems to be superior to serum pepsinogen and the most useful to detect those at high risk for gastric cancer among the examined miRNAs.

MiR-16 and U6snRNA are often used for normalisation to evaluate serum miRNAs as diagnostic markers for different tumours ([@bib2]). We used miRNA-16 as the endogenous control for data normalisation based on the fact that none of the miRNAs levels were significantly different between the two groups when using U6snRNA. Previous studies have also recommended miR-16 and miR-93 as suitable reference genes for serum miRNA analysis for gastric cancer and healthy controls ([@bib45]).

The major limitation of the present study is that it was a case--control study and a prospective cohort study should be done to confirm the association between the serum miRNAs levels and risk of gastric cancer development. Another limitation is that our investigation was not based on microarray profiling and there will be significant abnormalities of expression of other miRNAs related to development of gastric cancer. Further investigations *in vivo* and *in vitro* are required to obtain a comprehensive understanding role of serum miRNAs and the associated abnormalities in cellular signalling in carcinogenesis.

In conclusion, serum miRNAs may provide a new and stable biomarker to detect those at high risk for gastric cancer, and serum miR-106b and miR-21 may provide a novel and stable marker of increased risk for early gastric cancer after *H. pylori* eradication.
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![**Comparisons of serum miRNAs between the control group (Controls) and the high-risk group (Cancer) before and after eradication.** Horizontal bar=median; Box=25th--75th interquartile range; vertical lines=range of values. The cycle passing threshold (Ct) was recorded for each miRNA, and miR-16 was used as the endogenous control for data normalisation. *P-*values were calculated using the nonparametric Mann--Whitney *U-*test.](bjc2013596f1){#fig1}

![**Changes of serum miRNAs by *H. pylori* eradication in the control group (Controls) and the high-risk group (Cancer).** The cycle passing threshold (Ct) was recorded for each miRNA, and miR-16 was used as the endogenous control for data normalisation. *P-*values were calculated using the Wilcoxon\'s signed rank test.](bjc2013596f2){#fig2}

![**Changes of serum pepsinogen levels by *H. pylori* eradication in the control group (Controls) and the high-risk group (Cancer).** *P-*values were calculated using the Wilcoxon\'s signed rank test.](bjc2013596f3){#fig3}

![**Receiver--operator characteristic (ROC) curve analysis using serum miRNAs and pepsinogen for discriminating the high-risk group from the controls before or after *H. pylori* eradication.** Abbreviation: AUC=area under the ROC curve.](bjc2013596f4){#fig4}

###### Demographic and clinical characteristics of the patients

                                **Controls**   **Cancer**         ***P*****-values**
  ---------------------------- -------------- ------------ ---------------------------------
  Before eradication               *n*=64        *n*=64                     
  Age, mean (s.d.)               68.4 (8.3)    67.9 (8.2)   0.72[a](#t1-fn2){ref-type="fn"}
  Gender, male (%)               41 (64.1)     45 (70.3)    0.57[b](#t1-fn3){ref-type="fn"}
  Regular alcohol intake (%)     19 (28.1)     31 (48.4)    0.06[b](#t1-fn3){ref-type="fn"}
  Current smokers (%)            11 (17.1)      16 (25)     0.46[b](#t1-fn3){ref-type="fn"}
  After eradication                *n*=70        *n*=62                     
  Age, mean (s.d.)               66.7 (7.5)    67.8 (8.7)   0.44[a](#t1-fn2){ref-type="fn"}
  Gender, male (%)               47 (67.1)     44 (71.0)    0.71[b](#t1-fn3){ref-type="fn"}
  Regular alcohol intake (%)     27 (38.6)     25 (40.3)    0.85[b](#t1-fn3){ref-type="fn"}
  Current smokers (%)            11 (15.7)     19 (30.6)    0.08[b](#t1-fn3){ref-type="fn"}

*P-*values calculated using the unpaired *t*-test and Mantel--Haenszel *χ*^2^-analysis.

Unpaired *t*-test.

Mantel--Haenszel *χ*^2^-analysis.

###### Comparisons of serum miRNAs levels between the controls and the high-risk group

                             **Controls**        **Cancers**         ***P*****-values**
  -------------------------- ------------------- ------------------- --------------------
  **miR-106 (1 × 10^−2^)**                                           
  Before                     4.70 (2.14--9.02)   8.46 (2.73--29.7)   0.03
  After                      3.11 (2.15--6.33)   7.19 (3.08--29.1)   \<0.001
  **miR-21 (1 × 10^−2^)**                                            
  Before                     3.51 (2.81--6.36)   4.28 (2.41--10.0)   0.91
  After                      2.90 (2.03--3.61)   4.79 (2.51--7.21)   0.003
  **Let-7 (1 × 10^−2^)**                                             
  Before                     0.46 (0.18--0.82)   0.63 (0.27--2.41)   0.03
  After                      0.79 (0.36--1.49)   1.33 (0.44--3.73)   0.02
  **miR-214 (1 × 10^−2^)**                                           
  Before                     7.93 (0.83--43.1)   3.87 (1.11--25.9)   0.34
  After                      1.83 (0.57--17.6)   4.18(1.14--16.6)    0.14
  **miR-221 (1 × 10^−2^)**                                           
  Before                     1.24 (0.84--2.81)   0.94 (0.37--1.70)   0.11
  After                      3.11 (2.15--5.00)   2.66 (1.19--6.13)   0.26
  **miR-744 (1 × 10^−2^)**                                           
  Before                     1.20 (0.50--1.68)   0.85 (0.30--1.88)   0.30
  After                      1.44 (0.80--3.01)   1.20 (0.48--2.10)   0.22
  **miR-143 (1 × 10^−2^)**                                           
  Before                     0.33 (0.14--0.71)   0.45 (0.20--1.28)   0.29
  After                      0.28 (0.13--0.57)   0.41 (0.14--0.78)   0.40
  **miR-223**                                                        
  Before                     0.74 (0.22--3.94)   0.96 (0.18--2.11)   0.73
  After                      1.28 (0.75--1.94)   0.85 (0.28--1.86)   0.26
  **miR-375 (1 × 10^−2^)**                                           
  Before                     0.04 (0.02--0.23)   0.20 (0.02--0.45)   0.24
  After                      0.13 (0.08--0.25)   0.19 (0.03--0.37)   0.86
  **miR-17 (1 × 10^−2^)**                                            
  Before                     5.39 (3.89--6.86)   5.83 (4.03--8.18)   0.67
  After                      4.35 (3.57--5.96)   5.62 (3.60--6.78)   0.35
  **miR-194 (1 × 10^−2^)**                                           
  Before                     0.08 (0.05--0.22)   0.16 (0.11--0.29)   0.18
  After                      0.10 (0.05--0.19)   0.12 (0.08--0.32)   0.35
  **miR-25 (1 × 10^−2^)**                                            
  Before                     7.48 (1.87--13.3)   8.54 (5.90--16.0)   0.44
  After                      11.8 (8.43--16.8)   8.99 (5.47--11.5)   0.10
  **miR-92**                                                         
  Before                     2.04 (0.41--4.36)   2.37 (1.52--3.07)   0.80
  After                      3.16 (2.60--5.45)   2.33 (1.30--3.80)   0.09
  **miR-93 (1 × 10^−2^)**                                            
  Before                     3.84 (2.74--6.95)   5.18 (4.12--5.90)   0.32
  After                      5.22 (4.10--6.60)   6.15 (4.85--7.33)   0.52

Abbreviation: miRNA=micro-RNA.

*P-*values were calculated using the nonparametric Mann--Whitney *U*-test between the two groups.

The values indicated relative expression of miRNAs using miR-16 as an endogenous control.

###### Comparisons of serum pepsinogen levels between the controls and the high-risk group

                        **Controls**        **Cancers**         ***P*****-values**
  --------------------- ------------------- ------------------- --------------------
  **Pepsinogen I**                                              
  Before                55.3 (37.3--86.0)   35.1 (19.1--79.3)   0.01
  After                 41.9 (27.3--58.7)   31.7 (19.3--43.0)   0.01
  **Pepsinogen II**                                             
  Before                22.0 (15.7--33.5)   16.7 (8.40--26.4)   0.02
  After                 8.15 (6.13--10.8)   6.70 (5.10--8.80)   0.04
  **Pepsinogen I/II**                                           
  Before                2.50 (1.50--3.45)   2.20 (1.70--3.70)   0.97
  After                 5.25 (4.30--6.60)   4.70 (3.50--5.70)   0.01

*P-*values were calculated using the nonparametric Mann--Whitney *U*-test between the two groups.

###### Cutoff points of serum miRNAs and pepsinogen for screening for high risk of gastric cancer

  **Cutoff points**                     **Sensitivity (%)**   **Specificity (%)**   **Odds ratio (95% CI)**
  ------------------------------------- --------------------- --------------------- -------------------------
  **Before eradication**                                                            
  miR-106b \>0.075                      55.6                  70.3                  2.96 (1.42--6.15)
  miR-106b \>0.035 and Let-7 \>0.0035   60.3                  59.4                  2.22 (1.09--4.52)
  Pepsinogen I\<45                      62.3                  63.8                  2.91 (1.38--6.13)
  **After eradication**                                                             
  miR-106b \>0.032                      75.8                  51.4                  3.32 (1.57--7.00)
  miR-21\>0.04                          58.6                  86.1                  8.78 (2.65--29.1)
  miR-106b \>0.032 and miR-21\>0.02     69.0                  69.4                  5.05 (1.75--14.6)
  Pepsinogen I\<40                      69.5                  55.9                  2.89 (1.39--6.00)
  Pepsinogen I \<40 and I/II \<6        67.8                  61.8                  3.40 (1.63--7.08)

Abbreviations: CI=confidence interval; miRNA=micro-RNA.
